We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Multispan and Promega to Streamline GPCR Drug Screening Programs

MADISON, WISCONSIN (January 8, 2008)

Today Multispan and Promega agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening. The companies will combine Multispan GPCR cell lines and Promega bioluminescent technologies to create novel optimized GPCR screening protocols. The first tools will support cell lines and cAMP-Glo™ Assay for quantification of signal. Additional tools will be developed for cell-based assay detection.

This combination of validated biologic components with the most sensitive and dynamic luminescence assay detection technology for high-throughput screening will provide increased speed and efficiency in GPCR drug screening. Multispan is a leading supplier of high quality GPCR tools; Promega is the premier supplier of bioluminescent cell-based assay technologies for drug screening.

"Pre-optimized protocols will reduce assay development times, from months to days, helping deliver better GPCR targeted drugs faster", according to John Watson, Marketing Director of Pharma/Biotech at Promega. "Our suite of assay tools can be combined with Multispan’s validated GPCR cell lines to provide turnkey solutions for drug discovery scientists." Bioluminescent tools developed at Promega are routinely used to profile small molecule compounds, study druggable targets such as GPCRs, nuclear hormone receptors, proteases and kinases, and assess cell viability and cytotoxicity.

"Partnering with Promega further broadens the application of Multispan’s strong GPCR cell biology expertise. The combined offering from the two companies will benefit our customers enormously in drug discovery," said Dr. Helena Mancebo, President & CEO of Multispan.

The companies are planning joint scientific presentations and publications demonstrating the applications of the validated tools for GPCR drug discovery.

About Multispan
Multispan Inc. is a San Francisco Bay Area-based biotechnology company focused exclusively on GPCRs, the most important protein class of therapeutic targets. Privately held, and founded in 2004, Multispan has created the industry's largest collection of human GPCR clones and has engineered a large collection of GPCR-expressing cell lines, including the proprietary HEx™ series of High Expression cell lines. Multispan also offers custom services in compound profiling, antibody generation and cell line development. For more information about Multispan, visit www.multispaninc.com.

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.

For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or via our contact page.

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom